Whitehawk Therapeutics, Inc.

WHWK · United States

Share price · WHWK

$3.13-1.63 (-34.24%) 3M

close as of 2026-11-18 · 24h delayed · vol 284K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when WHWK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026-10.7%

    Nothing announced by WHWK that day or the session before.

  2. 6 Aug 2026+15.5%
  3. 13 May 2026+25.8%
  4. 16 Apr 2026+8.5%
  5. 14 Apr 2026+15.3%
  6. 27 Mar 2026-11.5%
  7. 5 Mar 2026+9.8%
  8. 27 Feb 2026+8.0%
  9. 4 Dec 2025+14.3%

Share of unusual movement by asset

For each asset, the share of WHWK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
HWK-007
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—65%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
PTK7 (protein tyrosine kinase 7)Antibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$18M$69M+ $101M short-term inv.$21M-$20M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$13M$85M+ $105M short-term inv.$17M-$15M operating cash flowreport ↗
2026-Q1$0$17M$35M+ $88M short-term inv.$22M-$22M operating cash flowreport ↗
2025-Q3$0$14M$38M+ $125M short-term inv.$18M-$15M operating cash flowreport ↗
2025-Q2$0$49M$145M+ $32M short-term inv.$53M-$53M operating cash flowreport ↗
2025-Q1$7.2M$8.8M$228M+ $3.5M short-term inv.—-$12M operating cash flowreport ↗
2024-Q3$7.2M$10M$31M+ $32M short-term inv.$13M-$16M operating cash flowreport ↗
2024-Q2$6.2M$13M$41M+ $37M short-term inv.$15M-$9.2M operating cash flowreport ↗
2024-Q1$5.3M$14M$54M+ $34M short-term inv.$18M-$20M operating cash flowreport ↗
2023-Q3$6.0M$12M$69M+ $51M short-term inv.$16M-$12M operating cash flowreport ↗
2023-Q2$6.2M$13M$68M+ $67M short-term inv.$18M-$17M operating cash flowreport ↗
2023-Q1$5.9M$11M$34M+ $117M short-term inv.$15M-$21M operating cash flowreport ↗
2022-Q3$4.3M$8.8M$135M+ $48M short-term inv.$14M-$8.2M operating cash flowreport ↗
2022-Q2$3.4M$7.7M$119M$18M-$11M operating cash flowreport ↗
2022-Q1$2.3M$6.8M$130M$14M-$19M operating cash flowreport ↗
2021-Q3$0$5.8M$161M$87M-$4.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$7.2M$91M$38M+ $108M short-term inv.$5.2M-$97M operating cash flowreport ↗

Whitehawk Therapeutics reported full-year 2025 revenue of $7.15M, down 72.5% YoY, with R&D spend of $90.96M, up 78.2% YoY. Cash and cash equivalents were $37.57M, and total cash, cash equivalents and short-term investments were $145.7M at year-end 2025. The company reported a full-year net loss of $20.6M, which included an $87.3M gain on the divestiture of AADI Subsidiary, and a quarterly net burn of $20.6M.

The company guided that its cash position is anticipated to fund operations into 2028. Phase 1 trials for PTK7-targeted ADC HWK-007 and MUC16-targeted ADC HWK-016 are actively recruiting, with initial results expected in 1H 2027, and HWK-206 is on track for an IND submission in mid-2026 with a Phase 1 start in Q3 2026. Whitehawk also announced the appointment of Margaret Dugan, MD as Chief Medical Officer and presented real-world data supporting PTK7 as a broadly expressed tumor target.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$26M$51M$29M+ $19M short-term inv.$16M-$60M operating cash flowreport ↗
2023-FY$24M$49M$63M+ $46M short-term inv.$16M-$60M operating cash flowreport ↗
2022-FY$15M$33M$39M+ $134M short-term inv.$15M-$50M operating cash flowreport ↗
2021-FY$1.1M$20M$149M+ $0 short-term inv.$28M-$22M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($2.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-15Giacobello Scott M. · CHIEF FINANCIAL OFFICERAward / grant (derivative)118,476——Form 4
2026-09-15Dugan Margaret · Chief Medical OfficerAward / grant (derivative)81,250——Form 4
2026-09-15Lennon David James · director, CHIEF EXECUTIVE OFFICERAward / grant (derivative)193,957——Form 4
2026-09-15Dornan David · Chief Scientific OfficerAward / grant (derivative)85,887——Form 4
2026-09-15BALL BRYAN · See remarksAward / grant (derivative)91,633——Form 4
2026-09-15Giacobello Scott M. · CHIEF FINANCIAL OFFICERAward / grant (derivative)118,476——Form 4
2026-09-15Dugan Margaret · Chief Medical OfficerAward / grant (derivative)81,250——Form 4
2026-09-15Lennon David James · director, CHIEF EXECUTIVE OFFICERAward / grant (derivative)193,957——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 62 reporting institutions held 35.2M shares ($122.4M, 59.6% of shares outstanding).

#InstitutionSharesValue
1QVT Financial LP4,615,709$15.9M
2ORBIMED ADVISORS LLC4,166,000$14.4M
3SUVRETTA CAPITAL MANAGEMENT, LLC3,700,000$12.8M
4ACUTA CAPITAL PARTNERS, LLC3,410,402$11.8M
5Avoro Capital Advisors LLC2,849,402$9.8M
6KVP Capital Advisors, LP2,165,997$7.5M
7Siren, L.L.C.2,082,000$7.2M
8Yu Fan2,070,000$7.1M
9STEMPOINT CAPITAL LP1,878,738$6.5M
10VANGUARD CAPITAL MANAGEMENT LLC1,315,770$4.5M
11ACORN CAPITAL ADVISORS, LLC1,139,363$3.9M
12Ally Bridge Group (NY) LLC817,939$2.8M
13Balyasny Asset Management L.P.550,441$1.9M
14GEODE CAPITAL MANAGEMENT, LLC457,540$1.6M
15RENAISSANCE TECHNOLOGIES LLC428,622$1.5M